133 related articles for article (PubMed ID: 20820909)
1. A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors.
Vilar E; Grünwald V; Schöffski P; Singer H; Salazar R; Iglesias JL; Casado E; Cullell-Young M; Baselga J; Tabernero J
Invest New Drugs; 2012 Feb; 30(1):299-305. PubMed ID: 20820909
[TBL] [Abstract][Full Text] [Related]
2. Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies.
Schöffski P; Dumez H; Ruijter R; Miguel-Lillo B; Soto-Matos A; Alfaro V; Giaccone G
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1397-403. PubMed ID: 21465314
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors.
Massard C; Salazar R; Armand JP; Majem M; Deutsch E; García M; Oaknin A; Fernández-García EM; Soto A; Soria JC
Invest New Drugs; 2012 Dec; 30(6):2318-26. PubMed ID: 22215532
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Baird RD; Kitzen J; Clarke PA; Planting A; Reade S; Reid A; Welsh L; López Lázaro L; de las Heras B; Judson IR; Kaye SB; Eskens F; Workman P; deBono JS; Verweij J
Mol Cancer Ther; 2009 Jun; 8(6):1430-7. PubMed ID: 19509256
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK
Invest New Drugs; 2012 Feb; 30(1):316-26. PubMed ID: 20839029
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
11. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
Ramnath N; Schwartz GN; Smith P; Bong D; Kanter P; Berdzik J; Creaven PJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):227-30. PubMed ID: 12655441
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W; Faivre S; Chieze S; Alexandre J; Lokiec F; Goldwasser F; Raymond E; Kahatt C; Taamma A; Weems G; MacDonald JR; Misset JL; Cvitkovic E
Invest New Drugs; 2006 Jul; 24(4):311-9. PubMed ID: 16683074
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
[TBL] [Abstract][Full Text] [Related]
18. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
[TBL] [Abstract][Full Text] [Related]
19. An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
Awada A; Thödtmann R; Piccart MJ; Wanders J; Schrijvers AH; Von Broen IM; Hanauske AR;
Eur J Cancer; 2003 Apr; 39(6):742-7. PubMed ID: 12651198
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]